O

Osanni Bio

Development-stage therapeutics platform advancing drug programs

Vice President - Regulatory Affairs

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • A bachelor's degree in a life science or related discipline is required.
  • At least 15 years of regulatory affairs experience in the biopharmaceutical industry, including at least 5 years in a regulatory leadership role managing teams and external partners.
  • Demonstrated success leading IND and CTA submissions and direct, face-to-face interactions with FDA and EMA.
  • Working knowledge of FDA regulations, ICH guidelines, EU regulatory requirements, and eCTD structure and publishing.
  • A strong understanding of CMC, nonclinical, and clinical regulatory requirements across the development lifecycle, with experience in small molecule, peptide, or biologic products.
  • Experience in a venture-backed, development-stage biotech or similarly fast-paced environment, with willingness to be both strategic and hands-on.
  • Ability to travel domestically and internationally as needed for agency meetings, team gatherings, and partner engagements, approximately 15 to 20%.

Responsibilities

  • Lead development and execution of global regulatory strategy for Osanni’s programs, beginning with MiraVi's ophthalmology pipeline, aligning regulatory pathways with clinical, CMC, and corporate objectives.
  • Serve as the primary regulatory liaison with FDA, EMA, and other health authorities; plan, prepare for, and lead agency interactions including pre-IND, End-of-Phase 2, Scientific Advice, and pre-NDA/BLA meetings.
  • Own planning, authoring, review, and timely submission of regulatory filings, including INDs, CTAs, amendments, annual reports, briefing documents, and, as programs advance, NDA/BLA and MAA submissions.
  • Partner with the Chief Medical Officer and Clinical Development to shape clinical development plans, protocol design, and endpoint strategy that support efficient regulatory approval.
  • Collaborate with Clinical Operations on protocol submissions, safety reporting obligations, and inspection readiness across global trial sites.
  • Work closely with CMC and Quality to define the regulatory strategy for drug substance and drug product.
  • Partner with Nonclinical, Biostatistics, and Drug Safety/Pharmacovigilance teams to ensure nonclinical packages, statistical analysis plans, and safety data meet regulatory expectations.
  • Identify and evaluate expedited pathways and designations, including Fast Track, Breakthrough Therapy, Orphan Drug, and PRIME, and lead related applications where appropriate.
  • Monitor the evolving regulatory landscape, including ophthalmology-specific guidance and precedent, and translate intelligence into risk assessments and actionable recommendations for leadership.
  • Build, lead, and develop the regulatory affairs function, including hiring and mentoring team members and selecting and managing regulatory consultants, CROs, and publishing vendors.
  • Manage multiple priorities in a fast-paced, evolving environment, ensuring deliverables are completed accurately and on time, while performing other related duties as required.

Desired Qualifications

  • An advanced degree such as a PhD, PharmD, MS, MPH, RN, or MD is strongly preferred; RAC certification is a plus.
  • Experience leading or making significant contributions to an NDA, BLA, or MAA approval is strongly preferred.
  • Ophthalmology drug development experience is strongly preferred, including familiarity with ophthalmic endpoints, formulations, and routes of administration such as topical and intravitreal.

About the Company

Osanni Bio

Development-stage therapeutics platform advancing drug programs

Osanni Bio uses a centralized innovation engine paired with a network of affiliate companies to discover, de-risk, and advance drug programs to proof-of-concept, then spins out successful programs as independent companies to scale. It generates drug concepts and progresses them to PoC through its central research engine and affiliate network. Unlike traditional pharma pipelines, it combines central science with a spin-out model to pursue capital-efficient, rapid PoC development. Its goal is to accelerate medicines in ophthalmology and cardiology with efficient progression to PoC and scalable programs.

Company size
11-50
Company stage
Series B
Total funding
$217M
Headquarters
San Francisco, CA
Founded
2023

Recently Posted Jobs

Explore more opportunities at Osanni Bio

See more jobs